Quarterly report pursuant to Section 13 or 15(d)

CONDENSED CONSOLIDATED BALANCE SHEETS (unaudited)

v3.2.0.727
CONDENSED CONSOLIDATED BALANCE SHEETS (unaudited) - USD ($)
$ in Thousands
Jun. 30, 2015
Dec. 31, 2014
Current assets:    
Cash and cash equivalents $ 15,781 $ 3,970
Accounts receivable $ 17 122
Marketable securities   1,975
Prepaid and other current assets $ 364 144
Mortgage note receivable, current portion 167 165
Total current assets 16,329 6,376
Property and equipment, net 215 284
Deposits 31 31
Mortgage note receivable, long-term portion 2,393 2,431
In process research and development 184,966 184,966
Goodwill 65,195 65,195
Total assets 269,129 259,283
Current liabilities:    
Accounts payable 838 299
Accrued expenses 381 394
Derivative liabilities 6,130 8,464
Total current liabilities 7,349 9,157
Long-term liabilities    
Deferred rent 62 62
Deferred tax liability 65,195 65,195
Total long-term liabilities 65,257 65,257
Total liabilities $ 72,606 74,414
Series A convertible preferred stock, $0.001 par value; 1,000 shares authorized, 0 and 1,000 issued and outstanding at June 30, 2015 and December 31, 2014, issued in the merger with RFS Pharma, LLC   178,218
Stockholders' equity:    
Series B convertible preferred stock, $.001 par value; 5,000 shares authorized; 0 and 1,000 shares issued and outstanding at June 30, 2015 and December 31, 2014, respectively   1
Common stock, $.001 par value; 800,000 and 200,000 shares authorized, 694,375 and 122,494 issued and outstanding as of June 30, 2015 and December 31, 2014, respectively $ 694 123
Additional paid-in capital $ 227,428 18,725
Accumulated other comprehensive income, net of tax   236
Accumulated deficit $ (31,599) (12,434)
Total stockholders' equity 196,523 6,651
Total liabilities and stockholders' equity $ 269,129 $ 259,283